Trial Profile
A Randomized and Open-label Study to Compare Efficacy and Safety after Switching from Tenofovir Disoproxi Fumarate to Tenofovir Alafenamide in Virologically Suppressed Chronic Hepatitis B Patients with Antiviral Resistance
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Tenofovir alafenamide (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- 29 Jun 2018 New trial record